[If Artificial Tears Aren't Enough. The Importance of Inflammatory Processes in Dry Eye Disease. Practical Aspects of an Anti-Inflammatory Therapy of Dry Eye Disease].

Dry eye disease (DED) is a heterogenous disease of the ocular surface. Multiple pathogenetic factors are responsible for the disease process, but DED is generally linked to an increase in the osmolarity of the tear film and to inflammation of the ocular surface. The significance of inflammatory processes in DED is highlighted in the most recent definition of dry eye in the Dry Eye Workshop (DEWS). It is therefore critically important for the management of dry eye disease to understand the pathomechanisms and therapeutic options for the treatment of inflammatory processes. This review summarizes our current knowledge on Inflammation associated with DED and provides practical recommendations for the diagnosis and monitoring of the disease, as well as the use of currently available therapeutic options to counteract inflammation in DED.
Competing Interests: U. Pleyer: Referent/Consultant für: Pharm Allergan GmbH, Santen GmbH, Théa Deutschland GmbH; G. Geerling: Referent/Consultant für Pharm Allergan GmbH, Santen GmbH, Shire, Tear Lab Inc, Tear Science, Théa Pharma GmbH; S. Schrader: Referent/Consultant für Santen GmbH und Tear Science; C. Jacobi: Referentin/Consultant für Théa Pharma GmbH, Santen GmbH und Shire Deutschland GmbH; F. Kimmich: Consultant für Santen GmbH; E. Messmer: Referentin/Consultant für: Pharm Allergan GmbH, Santen GmbH, Shire, Théa Deutschland GmbH.
(Georg Thieme Verlag KG Stuttgart · New York.)